Wildflower Marijuana Makes Research Agreement with Biologic Nutrigenomics

- December 9th, 2015

Wildflower Marijuana Inc. (CSE:SUN) announced that it’s entered into an agreement with Biologic Nutrigenomics Research Corp. under which Biologic will conduct medical research on Wildflower’s products and help with the development of new products.

Wildflower Marijuana Inc. (CSE:SUN) announced that it’s entered into an agreement with Biologic Nutrigenomics Research Corp. under which Biologic will conduct medical research on Wildflower’s products and help with the development of new products.
As quoted in the press release:

Wildflower has been developing cannabis products to address demands in the nutraceutical, pharmacological and recreational cannabis sectors. The company intends to bring products to market that are backed by solid scientific study demonstrating their efficacy. By using a science-based approach, the company will be able to further enhance the effectiveness of all its products.

Franco Cavaleri, president and chief science officer at Biologic, commented:

As much as the current movement to legalize and make cannabis more readily available is an exciting business prospect, it is more important to take a serious leadership role in the mining of this natural medicine’s full therapeutic potential to advance medical research and treatment of disease. Cannabis comprises a plethora of constituents that range in pharmacological activity from anti-inflammatory, analgesic (pain killing) and anti-cancer to neuro-protective and neuro-corrective. However, clinical and wet lab research reliability and repeatability have fallen short due to lack of standardization and sophistication of historical research models. With a corporate mission dedicated to extract the full pharmacological potential of this medicinal agent and some insight that gives us a head start with the right biological mechanisms and models, research using formal medical models to investigate novel cannabinoid-signalling pathways in the framework of complex disease pathologies to improve efficacy, reliability and acceptability in mainstream medicine [will allow the company] to better serve humanity and global health care with reliable, low-risk medicines exclusive to the Wildflower brand.

Click here to read the full Wildflower Marijuana Inc. (CSE:SUN) press release.

Get the latest Cannabis Investing stock information

Leave a Reply